A 21st Century Approach to Treating Basal Cell Carcinoma - Patient Follow-Up

Dr. Ragini Kudchadkar is an Assistant Member at Moffitt Cancer Center and an Assistant Professor at University of South Florida College of Medicine's Department of Oncologic Sciences. She completed her medical school and internal medicine training at Emory University in Atlanta, Georgia, and subsequently trained in hematology/oncology at the University of Colorado prior to joining the Moffitt faculty. Dr. Kudchadkar's primary interest is in clinical research investigating signal transduction inhibitors in melanoma as well as a secondary interest in rare cutaneous malignancies such basal cell carcinomas.

Karl D. Lewis, MD, graduated from Albany Medical College and completed his residency in internal medicine at the University of California, Irvine. From there he spent two years as a fellow in hematology/oncology at the University of Colorado Health Sciences Center. Dr. Lewis is Associate Professor of Medicine and Associate Director, Cutaneous Oncology Program at the University of Colorado Denver, Division of Medical Oncology. He is a diplomat in medical oncology.
 
Dr. Lewis is a member of the American Society of Clinical Oncology, the Southwest Oncology Group and the Society for Melanoma Research. Author of over 50 publications, Dr. Lewis has also presented more than 50 lectures and more than 35 abstracts. He is also an ad hoc reviewer for the journals Cancer, Cancer Investigation, Current Drug Targets, Expert Opinion on Biological Therapy, and The Oncologist.

Jean Y. Tang, MD, PhD, graduated from Stanford University School of Medicine and completed an internship at Santa Clara Valley Medical Center. From there, Dr. Tang completed a residency in dermatology at Stanford University School of Medicine, and a post-doctoral fellowship at University of California, San Francisco. Dr. Tang is currently an Assistant Professor at Stanford University in the Department of Dermatology.
                    
Author of over 40 publications, Dr. Tang currently is co-investigator on two research grants funded by the National Institutes of Health, for "MIM Function in Epithelial Neoplasia" and a continuing follow-up of participants of the WHI clinical trials. She also is the principal investigator on the Damon Runyon Clinical Investigator Award, the goal of which is to determine the genetic mutations driving drug resistance in BCC tumors from patients.